Invest In Biomed is a unique Eurobiomed program that assists innovative health companies in consolidating their fundraising approach and tools, and connects them with specialized investors in the sector. On the occasion of the launch of the 10th edition of this program, we are featuring entrepreneurs who have benefited from it.
Yoann Valorge, co-founder and CEO of NxNeuro, participated in the 8th edition of Eurobiomed's Invest In Biomed program in 2023. This experience culminated in a successful fundraising round in May 2024. He reflects on the contributions of this support program dedicated to financing health startups.
How has access to specialized healthcare investment funds been crucial for your fundraising?
In the healthcare sector, particularly for medical devices, few funds genuinely commit to seed funding. The program enabled us to meet qualified investors, which was particularly valuable in a challenging fundraising environment during 2023-2024. Indeed, one of the funds we met through Invest In Biomed became our lead investor, thereby lending credibility to our proposal and attracting our second investor.
How did the program assist you in tailoring your pitch to investor expectations?
The program enabled us to recalibrate our presentation to better align with investor expectations. This involved adjusting our terminology and presentation style. This alignment between our needs and investor expectations was crucial for optimizing our communication.
What was the contribution of the multi-expertise support provided?
We benefited from complementary expertise in finance, business, and intellectual property. These diverse perspectives allowed us to strengthen our case and validate our approach. The experts specifically assisted us in refining our presentation on each of these aspects, by adopting appropriate terminology and highlighting elements pertinent to investors.
SIMILAR ARTICLES:
Amaury Ciurana (REEV): “The Invest In Biomed program offered us a privileged framework to build trusting relationships with our investors”
Arnaud Debains and Sandrine Isz (BOYDSense): 'Invest In Biomed enabled us to better articulate our story.'
